PTC Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 1K
- Market Cap
- $2.7B
- Website
- http://www.ptcbio.com
- Introduction
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 279
- Registration Number
- NCT02139306
- Locations
- 🇺🇸
Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
Study of Ataluren (PTC124) in Cystic Fibrosis
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 61
- Registration Number
- NCT02107859
- Locations
- 🇺🇸
University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸Miller Children's Hospital Long Beach, Long Beach, California, United States
🇺🇸Denver Children's Hospital, Aurora, Colorado, United States
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 219
- Registration Number
- NCT02090959
- Locations
- 🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 230
- Registration Number
- NCT01826487
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇫🇷Hopital Necker - Enfants Malades, Paris, France
🇮🇹Bambino Gesu Hospital, Rome, Italy
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
- Conditions
- Interventions
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT01728064
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of South Florida, Tampa, Florida, United States
Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT01721733
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Stanford University, Palo Alto, California, United States
Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
- Conditions
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 94
- Registration Number
- NCT01557400
- Locations
- 🇦🇺
Royal Children's Hospital, Parkville, Melbourne, Australia
🇸🇪Astrid Lindgren Pediatric Hospital, Stockholm, Sweden
🇮🇹Ospedale Maggiore Policlinico in Milan, Milan, Italy
EPI-743 for Mitochondrial Respiratory Chain Diseases
- Conditions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- PTC Therapeutics
- Registration Number
- NCT01370447
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Emory University, Decatur, Georgia, United States
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 270
- Registration Number
- NCT01247207
- Locations
- 🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸Rush Univ Medical Center, Chicago, Illinois, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
Ataluren for Nonsense Mutation Methylmalonic Acidemia
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 11
- Registration Number
- NCT01141075
- Locations
- 🇮🇹
Istituti Clinici di Perfezionamento, Milano, Milan, Italy
🇧🇪ZNA Queen Paola Child Hospital and Provincial Centre for Metabolic Disorders, Antwerp, Belgium
🇫🇷Hôpital Edouard Herriot, Lyon, France